Seleccionar página

Quotes.ino.com needs to review the security of your connection before proceeding. The compound annual growth rate measures an investment’s annual growth rate over https://dotbig.com/ a period of time, assuming profits are reinvested at the end of each year. IBD Videos Get market updates, educational videos, webinars, and stock analysis.

You can read more about the power of momentum in assessing share price movements on Stockopedia. Biogen’s BIIB, +4.96% stock is rising again as investors double down on the company’s promising yet still experimental treatment for Alzheimer’s disease. Even though many stocks have fallen sharply in price, not Forex news all are bargains — investors must remains selective. To see a complete breakdown of any of the ETFs included in the table below, including sector, market cap, and country allocations, click on the ticker symbol. Biogen reported an EPS of $4.77 in its last earnings report, beating expectations of $4.126.

Biogen Inc stock

Only 17 people have searched for BIIB on MarketBeat in the last 30 days. MarketBeat has tracked 5 news articles for Biogen this week, compared to 13 articles on an average week.

Industry, Sector and Symbol

Gurus may be added or dropped from the GuruFocus site at any time. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily. Biogen, Inc. is a BIIB stock forecast biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis, SPINRAZA for the treatment of spinal muscular atrophy, and FUMADERM for the treatment of severe plaque psoriasis.

According to analysts’ consensus price target of $299.75, Biogen has a forecasted downside of 1.8% from its current price of $305.15. The company’s average rating score is 2.71, and is based on 20 buy ratings, 8 hold ratings, and no sell ratings.

Robert Francis, former CEO of Sandoz and an executive at Novartis AG and former executive at Biogen Inc. , will beco… If a user or application submits more than 10 requests per second, further requests from the IP address may be limited for a brief period. Once the rate of requests has dropped below the threshold https://www.ig.com/en/forex/what-is-forex-and-how-does-it-work for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website. By using this site, you are agreeing to security monitoring and auditing.

Visual History Of The Dow Jones Industrial Average (DIA)

An analysis of the technical chart of Biogen Inc. shows the stock could be set to rebound by about 7%, giving shares the chance to rise back towards $282 from its price of roughly $263, a jump of about 7.5%. Biogen shares were up by roughly 1% on April 24, after stock price of Biogen Inc the company reported better than expected first-quarter earnings per share, and revenue that was in line with estimates. Biogen and Idec merged in 2003, combining forces to market Biogen’s multiple sclerosis drug Avonex and Idec’s cancer drug Rituxan.

  • The company is scheduled to release its next quarterly earnings announcement on Thursday, February 2nd 2023.
  • The Biotech sector has been dragged down by Biogen since the end of January, and that is because it is a big component within the NASDAQ Biotech ETF , accounting for a nearly 7.5% weighting.
  • It has a portfolio of medicines to treat multiple sclerosis , spinal muscular atrophy and Alzheimer’s disease.
  • Dr. Howard Fillit, chief science officer for the Alzheimer’s Drug Discovery Foundation, said Biogen’s results are promising, but only offer a first step in treating the disease.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the dotbig PE, the more expensive the stock is. Biogen Inc. shares BIIB, -0.43% rose 4.7% in premarket trade Monday, after MorphoSys and partner Roche said a trial of a treatment for Alzheimer’s disease failed to meet its main goal.

Biogen Inc at Evercore ISI HealthCONx Conference (Virtual)

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. One share of BIIB stock can currently be purchased for approximately $305.15. https://dotbig.com/markets/stocks/BIIB/ The company is scheduled to release its next quarterly earnings announcement on Thursday, February 2nd 2023. Sign-up to receive the latest news and ratings for Biogen and its competitors with MarketBeat’s FREE daily newsletter.

Biogen Names Christopher Viehbacher President and Chief Executive Officer

The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA. Key multiple sclerosis/MS drugs in its portfolio are Tecfidera, Vumerity, Avonex, Plegridy, Fampyra and Tysabri. Other approved/marketed products include Fumaderm , Spinraza (spinal muscular atrophy ) and Aduhelm (Alzheimer’s disease). Incorporated in 1978, Massachusetts-based Biogen, Inc. is a biopharmaceutical company, which discovers, develops, and delivers therapies for the treatment of neurological and neurodegenerative diseases. It offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, VUMERITY, and FAMPYRA for the treatment of multiple sclerosis; SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of severe plaque psoriasis. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis, SPINRAZA for the treatment of spinal muscular atrophy, and FUMADERM for the treatment of seve… Intraday Data provided by FACTSET and subject to terms of use.

Billionaire investor and hedge fund manager Steve Cohen’s Point 72 Asset Management has disclosed some interesting stakes in… 394 employees have rated Forex news Biogen Chief Executive Officer Michel Vounatsos on Glassdoor.com. Michel Vounatsos has an approval rating of 86% among the company’s employees.

It is focused on discovering, developing and delivering therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. It has a portfolio of medicines to treat multiple sclerosis , spinal muscular atrophy and Alzheimer’s disease. It has an affiliated registered investment adviser, which serves as the subadviser https://dotbig.com/markets/stocks/BIIB/ to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company’s price per share by its earnings per share. Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis https://dotbig.com/ ; SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer’s disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. It offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis,…